ALFA Filings
Every announcement, straight from the exchange
Every Granules India earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
10 announcements
Granules India Q1 FY27 results show strong performance with Revenue growing 22% YoY and PAT up 60%, driven by a significant mix shift towards high-margin Complex Generics.
Granules India delivered record Q1 results, pivoting from volume-driven to a higher-margin complex generic and peptide-led platform. Profitability grew 60% YoY despite regulatory headwinds at Gagillapur, highlighting strong execution and diversification into regulated markets.
Granules India delivered a strong Q1FY27 with 22% YoY revenue growth and 60% PAT growth, driven by a portfolio shift toward high-margin Complex Generics.
Granules India reported Q3FY26 revenue of ₹13,879 Mn (up 22% YoY) and PAT of ₹1,502 Mn (up 28% YoY), driven by Finished Dosage growth in North America and Europe.
Granules India reported Q3FY26 revenue of ₹13,879 Mn with a 22% YoY growth. Strategy focuses on shifting from integrated to complex generics, supported by R&D and US portfolio expansion.
Granules India delivered record performance in FY26, crossing INR 5,000 Cr revenue with 65% gross margins. Management focused on complex generics and the successful integration of Senn Chemicals' peptide business.
Granules India delivered a strong Q3FY26 with 22% YoY revenue growth, despite a temporary EBITDA loss in its Acyl-S peptide CDMO business. Operating performance improved on execution and leverage.
Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift toward high-margin Complex Generics and Peptide CDMO.
Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift towards high-margin Complex Gx and Peptide CDMO segments.
Granules India achieved a landmark FY26 with revenue surpassing ₹50,000 Mn, driven by a structural shift toward high-margin Complex Gx and Peptide CDMO.